RESUMEN
Malaria is a major tropical disease where important needs are to mitigate symptoms and to prevent the establishment of infection. Cyclopeptides containing N-methyl amino acids with in vitro activity against erythrocytic forms as well as liver stage are presented. The synthesis, parasitological characterization, physicochemical properties, in vivo evaluation, and mice pharmacokinetics are described.
RESUMEN
Spread of parasite resistance to artemisinin threatens current frontline antimalarial therapies, highlighting the need for new drugs with alternative modes of action. Since only 0.2-1% of asexual parasites differentiate into sexual, transmission-competent forms, targeting this natural bottleneck provides a tangible route to interrupt disease transmission and mitigate resistance selection. Here we present a high-throughput screen of gametogenesis against a ~70,000 compound diversity library, identifying seventeen drug-like molecules that target transmission. Hit molecules possess varied activity profiles including male-specific, dual acting male-female and dual-asexual-sexual, with one promising N-((4-hydroxychroman-4-yl)methyl)-sulphonamide scaffold found to have sub-micromolar activity in vitro and in vivo efficacy. Development of leads with modes of action focussed on the sexual stages of malaria parasite development provide a previously unexplored base from which future therapeutics can be developed, capable of preventing parasite transmission through the population.
Asunto(s)
Antimaláricos/análisis , Evaluación Preclínica de Medicamentos , Ensayos Analíticos de Alto Rendimiento/métodos , Malaria/parasitología , Malaria/transmisión , Parásitos/fisiología , Animales , Antimaláricos/química , Antimaláricos/farmacología , Conducta Alimentaria , Femenino , Gametogénesis/efectos de los fármacos , Células Hep G2 , Humanos , Masculino , Ratones , Parásitos/efectos de los fármacos , Fenotipo , Reproducibilidad de los Resultados , Relación Estructura-ActividadRESUMEN
Since the appearance of resistance to the current front-line antimalarial treatments, ACTs (artemisinin combination therapies), the discovery of novel chemical entities to treat the disease is recognized as a major global health priority. From the GSK antimalarial set, we identified an aminoxadiazole with an antiparasitic profile comparable with artemisinin (1), with no cross-resistance in a resistant strains panel and a potential new mode of action. A medicinal chemistry program allowed delivery of compounds such as 19 with high solubility in aqueous media, an acceptable toxicological profile, and oral efficacy. Further evaluation of the lead compounds showed that in vivo genotoxic degradants might be generated. The compounds generated during this medicinal chemistry program and others from the GSK collection were used to build a pharmacophore model which could be used in the virtual screening of compound collections and potentially identify new chemotypes that could deliver the same antiparasitic profile.
Asunto(s)
2,2'-Dipiridil/análogos & derivados , Antimaláricos/farmacología , Oxadiazoles/farmacología , 2,2'-Dipiridil/administración & dosificación , 2,2'-Dipiridil/síntesis química , 2,2'-Dipiridil/farmacología , 2,2'-Dipiridil/toxicidad , Animales , Antimaláricos/administración & dosificación , Antimaláricos/síntesis química , Antimaláricos/toxicidad , Atovacuona/farmacología , Cloroquina/farmacología , Diseño de Fármacos , Femenino , Humanos , Hidrazinas/metabolismo , Ratones , Pruebas de Mutagenicidad , Mutágenos/metabolismo , Oxadiazoles/administración & dosificación , Oxadiazoles/síntesis química , Oxadiazoles/toxicidad , Parasitemia/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Pirimetamina/farmacología , Relación Estructura-ActividadRESUMEN
Antiparasitic oral drugs have been associated to lipophilic molecules due to their intrinsic permeability. However, these kind of molecules are associated to numerous adverse effects, which have been extensively studied. Within the Tres Cantos Antimalarial Set (TCAMS) we have identified two small, soluble and simple hits that even presenting antiplasmodial activities in the range of 0.4-0.5 µM are able to show in vivo activity.
RESUMEN
A novel family of antimalarials based on the 4(1H)-pyridone scaffold is described. The compounds display potent antimalarial activity against Plasmodium falciparum in vitro and in vivo. Like atovaquone, 4(1H)-pyridones exert their antimalarial action by inhibiting selectively the electron-transport chain in P. falciparum at the cytochrome bc1 level (complex III). However, despite the similar mechanism of action, no cross-resistance with atovaquone has been found, suggesting that the binding mode of 4(1H)-pyridones might be different from that of atovaquone. The medicinal chemistry program, focused on improving potency and physicochemical properties, ultimately led to the discovery of GSK932121, which was progressed efficiently into first time in human studies. However, progression of GSK932121 was terminated when new toxicology results were obtained in the rat with a soluble phosphate prodrug of the candidate, indicating a potentially narrow therapeutic index.
Asunto(s)
Antimaláricos/química , Antimaláricos/farmacología , Complejo III de Transporte de Electrones/antagonistas & inhibidores , Malaria/tratamiento farmacológico , Plasmodium/enzimología , Piridonas/química , Piridonas/farmacología , Animales , Antimaláricos/uso terapéutico , Complejo III de Transporte de Electrones/metabolismo , Humanos , Malaria/parasitología , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/parasitología , Plasmodium/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/enzimología , Piridonas/uso terapéuticoRESUMEN
Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2-cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.